{"title": "Gerald Edward Archer", "author": null, "url": null, "hostname": null, "description": "Gerald Edward Archer | Scholars@Duke profile: Publications", "sitename": null, "date": "1995-03-28", "cleaned_text": "Selected Publications Journal Article Npj Vaccines \u00b7 January 18, 2021 Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune response. Several cancers ex ... [A conjoined universal helper epitope can unveil antitumor effects Nat Commun \u00b7 June 24, 2020 The application of adoptive T cell therapies, including those using chimeric antigen receptor (CAR)-modified T cells, to solid tumors requires combinatorial strategies to overcome immune suppression associated with the tumor microenvironment. Here we test ... [Oncolytic virus-derived type I interferon restricts CAR [Full text](https://dx.doi.org/10.1038/s41467-020-17011-z) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/32581235) [Cite](/publication/1448889#cite) Journal Article Plos One \u00b7 2020 We recently reported the development of a fully-human, CD3-binding bispecific antibody for immunotherapy of malignant glioma. To translate this therapeutic (hEGFRvIII-CD3- bi-scFv) to clinical trials and to help further the translation of other similar CD3 ... [GLP toxicology study of a fully-human 20, 2019 e13526 Background: Recurrence of high-grade glioma (HGG) (WHO grade III-IV) is a nearly universal phenomenon and necessitates the development of new therapeutic modalities. Two possible immunotherapeutic modalities are checkpoint ... [Safety of nivolumab in ](/publication/1415015) [Full text](https://dx.doi.org/10.1200/jco.2019.37.15_suppl.e13526) [Cite](/publication/1415015#cite) Journal \u00b7 January 1, 2019 PURPOSE: Chimeric antigen receptor (CAR) T cells have shown promise against solid tumors, but their efficacy has been limited, due in part, to immunosuppression by CD4+FoxP3+ regulatory T cells (Tregs). Although lymphodepletion is commonly used to deplete ... [Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. ](/publication/1358175) [Full Neurosci \u00b7 October 2018 Convection Enhanced Delivery (CED) infuses therapeutic agents directly into the intracranial area continuously under pressure. The convection improves the distribution of therapeutics such as those aimed at brain tumors. Although CED successfully delivers ... [Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. ](/publication/1334902) [Full text](https://dx.doi.org/10.1016/j.jocn.2018.06.005) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/30041899) [Cite](/publication/1334902#cite) Journal Article Molecular Therapy Methods and Clinical Development \u00b7 September 21, 2018 Replication-competent retrovirus (RCR) is a safety concern for individuals treated with retroviral gene therapy. RCR detection assays are used to detect RCR in manufactured vector, transduced cell products infused into research subjects, and in the researc ... [Screening Clinical Cell Products for Replication Competent Retrovirus: National Gene Vector Biorepository Experience ](/publication/1350619) [Full text](https://dx.doi.org/10.1016/j.omtm.2018.08.006) [Cite](/publication/1350619#cite) Journal Article Clin Cancer Res \u00b7 August 1, 2018 Purpose: Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates that if appropriately redirected, T cells can precisely eradicate tumors. Here we report the rational development of a ... [A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Journal Article Cancer Res \u00b7 January 1, 2018 Median survival for glioblastoma (GBM) remains <15 months. Human cytomegalovirus (CMV) antigens have been identified in GBM but not normal brain, providing an unparalleled opportunity to subvert CMV antigens as tumor-specific immunotherapy Polyfunctionality Article \u00b7 2018 Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges that are even more significant. In orde ... [Temozolomide lymphodepletion enhances CAR abundance and 27, 2017 Objective: To evaluate the feasibility and safety of administering brain tumor stem cell (BTSC) mRNA-loaded dendritic cells (DC) to patients with recurrent GBM. Background: BTSC CD133+ contribute to GBM propagation chemo-radiation ... [Tumor stem cell RNA-leaded dedritic cell vaccine for a phase 1 trail. ](/publication/1459087) [Link to item](https://n.neurology.org/content/88/16_Supplement/S41.004) [Cite](/publication/1459087#cite) Journal Article Clin Cancer Res \u00b7 April 15, 2017 Purpose: Patients with glioblastoma have less than 15-month median survival despite surgical resection, high-dose radiation, and chemotherapy with temozolomide. We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can e BISPECIFIC GLIOMA ](/publication/1252406) [Link to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398604102127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [Cite](/publication/1252406#cite) Conference Journal of Clinical Oncology \u00b7 May 20, 2016 ackground: The inherent biologic specificity of immunotherapy offers the prospect of targeting neoplastic cells more precisely. Dendritic cells (DCs) are endowed with an extraordinary ability to activate CD4+ and CD8+ T-cells, and DCs loaded with combination against cytomegalovirus (CMV) Immunol Immunother \u00b7 February 2016 Regulatory B cells that secrete IL-10 (IL-10(+) Bregs) represent a suppressive subset of the B cell compartment with prominent anti-inflammatory capacity, capable of suppressing cellular and humoral responses to cancer and vaccines. B lymphocyte stimulator ... [Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma undergoing immunotherapy. June 2015 BACKGROUND: The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in 30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists of the unique EGFRvIII peptide sequence conjugated of rindopepimut (CDX-110) glioblastoma: [Full text](https://dx.doi.org/10.1093/neuonc/nou348) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/25586468) [Cite](/publication/1056232#cite) Conference Journal of Clinical Oncology \u00b7 May 20, 2015 [Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory text](https://dx.doi.org/10.1200/jco.2015.33.15_suppl.e13030) [Cite](/publication/1084025#cite) Journal Article Cancer Immunol Res \u00b7 April 2015 Therapeutic vaccination of patients with cancer-targeting tumor-associated antigens is a promising strategy for the specific eradication of invasive malignancies with minimal toxicity to normal tissues. However, as increasingly potent modalities for stimul ... [Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic \u00b7 March 19, 2015 After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and injected back patients vacci ... [Tetanus toxoid and CCL3 \u00b7 July 2014 Immunotherapy promises an exquisitely precise therapeutic approach, and substantial evidence suggests that activated T cells can eradicate large tumors, even within the \"immunologically privileged\" text](https://dx.doi.org/10.1093/neuonc/nou208.65) [Link to [Cite](/publication/1042440#cite) Journal Article Npj \u00b7 January 18, 2021 Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune response. Several cancers ex ... [A conjoined universal helper epitope can unveil antitumor effects Nat Commun \u00b7 June 24, 2020 The application of adoptive T cell therapies, including those using chimeric antigen receptor (CAR)-modified T cells, to solid tumors requires combinatorial strategies to overcome immune suppression associated with the tumor microenvironment. Here we test ... [Oncolytic virus-derived type I interferon restricts CAR [Full text](https://dx.doi.org/10.1038/s41467-020-17011-z) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/32581235) [Cite](/publication/1448889#cite) Journal Article Plos One \u00b7 2020 We recently reported the development of a fully-human, CD3-binding bispecific antibody for immunotherapy of malignant glioma. To translate this therapeutic (hEGFRvIII-CD3- bi-scFv) to clinical trials and to help further the translation of other similar CD3 ... [GLP toxicology study of a fully-human 20, 2019 e13526 Background: Recurrence of high-grade glioma (HGG) (WHO grade III-IV) is a nearly universal phenomenon and necessitates the development of new therapeutic modalities. Two possible immunotherapeutic modalities are checkpoint ... [Safety of nivolumab in ](/publication/1415015) [Full text](https://dx.doi.org/10.1200/jco.2019.37.15_suppl.e13526) [Cite](/publication/1415015#cite) Journal \u00b7 January 1, 2019 PURPOSE: Chimeric antigen receptor (CAR) T cells have shown promise against solid tumors, but their efficacy has been limited, due in part, to immunosuppression by CD4+FoxP3+ regulatory T cells (Tregs). Although lymphodepletion is commonly used to deplete ... [Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. ](/publication/1358175) [Full Neurosci \u00b7 October 2018 Convection Enhanced Delivery (CED) infuses therapeutic agents directly into the intracranial area continuously under pressure. The convection improves the distribution of therapeutics such as those aimed at brain tumors. Although CED successfully delivers ... [Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. ](/publication/1334902) [Full text](https://dx.doi.org/10.1016/j.jocn.2018.06.005) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/30041899) [Cite](/publication/1334902#cite) Journal Article Molecular Therapy Methods and Clinical Development \u00b7 September 21, 2018 Replication-competent retrovirus (RCR) is a safety concern for individuals treated with retroviral gene therapy. RCR detection assays are used to detect RCR in manufactured vector, transduced cell products infused into research subjects, and in the researc ... [Screening Clinical Cell Products for Replication Competent Retrovirus: National Gene Vector Biorepository Experience ](/publication/1350619) [Full text](https://dx.doi.org/10.1016/j.omtm.2018.08.006) [Cite](/publication/1350619#cite) Journal Article Clin Cancer Res \u00b7 August 1, 2018 Purpose: Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates that if appropriately redirected, T cells can precisely eradicate tumors. Here we report the rational development of a ... [A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Journal Article Cancer Res \u00b7 January 1, 2018 Median survival for glioblastoma (GBM) remains <15 months. Human cytomegalovirus (CMV) antigens have been identified in GBM but not normal brain, providing an unparalleled opportunity to subvert CMV antigens as tumor-specific immunotherapy Polyfunctionality Article \u00b7 2018 Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges that are even more significant. In orde ... [Temozolomide lymphodepletion enhances CAR abundance and 27, 2017 Objective: To evaluate the feasibility and safety of administering brain tumor stem cell (BTSC) mRNA-loaded dendritic cells (DC) to patients with recurrent GBM. Background: BTSC CD133+ contribute to GBM propagation chemo-radiation ... [Tumor stem cell RNA-leaded dedritic cell vaccine for a phase 1 trail. ](/publication/1459087) [Link to item](https://n.neurology.org/content/88/16_Supplement/S41.004) [Cite](/publication/1459087#cite) Journal Article Clin Cancer Res \u00b7 April 15, 2017 Purpose: Patients with glioblastoma have less than 15-month median survival despite surgical resection, high-dose radiation, and chemotherapy with temozolomide. We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can e BISPECIFIC GLIOMA ](/publication/1252406) [Link to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398604102127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [Cite](/publication/1252406#cite) Conference Journal of Clinical Oncology \u00b7 May 20, 2016 ackground: The inherent biologic specificity of immunotherapy offers the prospect of targeting neoplastic cells more precisely. Dendritic cells (DCs) are endowed with an extraordinary ability to activate CD4+ and CD8+ T-cells, and DCs loaded with combination against cytomegalovirus (CMV) Immunol Immunother \u00b7 February 2016 Regulatory B cells that secrete IL-10 (IL-10(+) Bregs) represent a suppressive subset of the B cell compartment with prominent anti-inflammatory capacity, capable of suppressing cellular and humoral responses to cancer and vaccines. B lymphocyte stimulator ... [Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma undergoing immunotherapy. June 2015 BACKGROUND: The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in 30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists of the unique EGFRvIII peptide sequence conjugated of rindopepimut (CDX-110) glioblastoma: [Full text](https://dx.doi.org/10.1093/neuonc/nou348) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/25586468) [Cite](/publication/1056232#cite) Conference Journal of Clinical Oncology \u00b7 May 20, 2015 [Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory text](https://dx.doi.org/10.1200/jco.2015.33.15_suppl.e13030) [Cite](/publication/1084025#cite) Journal Article Cancer Immunol Res \u00b7 April 2015 Therapeutic vaccination of patients with cancer-targeting tumor-associated antigens is a promising strategy for the specific eradication of invasive malignancies with minimal toxicity to normal tissues. However, as increasingly potent modalities for stimul ... [Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic \u00b7 March 19, 2015 After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and injected back patients vacci ... [Tetanus toxoid and CCL3 \u00b7 July 2014 Immunotherapy promises an exquisitely precise therapeutic approach, and substantial evidence suggests that activated T cells can eradicate large tumors, even within the \"immunologically privileged\" July 2014 Dendritic cell (DC) vaccine efficacy is limited by suboptimal migration to vaccine site-draining lymph nodes (VDLNs). In mice, vaccine site conditioning with inflammatory cytokines or mature DCs increases DC trafficking and the induction of antigen-specifi ... [RANDOMIZATION OF PATIENTS SITE PRE-CONDITIONING WITH TETANUS-DIPHTHERIA TOXOID SYSTEMICALLY ENHANCES MIGRATION AND THERAPEUTIC EFFECT OF CYTOMEGALOVIRUS VACCINE to item](http://www.ncbi.nlm.nih.gov/pubmed/25165316) [Cite](/publication/1042441#cite) 20, T-cell inhibition plus antitumor immunotherapy targeted text](https://dx.doi.org/10.1200/jco.2014.32.15_suppl.3069) [Cite](/publication/1084030#cite) Res \u00b7 May 15, 2014 PURPOSE: Despite aggressive conventional therapy, glioblastoma (GBM) remains uniformly lethal. Immunotherapy, in which the immune system is harnessed to specifically attack malignant cells, offers a treatment option with less toxicity. The expression of cy ... [Recognition and killing of autologous, primary glioblastoma tumor \u00b7 2014 Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment given its potential to specifically target tumor tissue while sparing the normal bra ... [EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive Immunol Immunother \u00b7 November 2013 Adoptive cell transfer (ACT) using ex vivo-expanded anti-tumor T cells such as tumor-infiltrated lymphocytes or genetically engineered T cells potently eradicates established tumors. However, these two approaches possess obvious limitations. Therefore, we ... [A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey model. ](/publication/961875) item](https://www.ncbi.nlm.nih.gov/pubmed/23982483) [Cite](/publication/961875#cite) Journal Article J Immunol Methods \u00b7 September 30, 2013 Developments in the field of bispecific antibodies have progressed rapidly in recent years, particularly in their potential role for the treatment of malignant disease. However, manufacturing stable molecules has proven to be costly and time-consuming, whi ... [Rational design and generation of Cancer Immunol Res \u00b7 September 2013 A major mechanism by which human regulatory T cells (T(regs)) have been shown to suppress and kill autologous immune cells is through the granzyme-perforin pathway. However, it is unknown whether T(regs) also possess the capacity to kill tumor cells using ... [Human regulatory T cells kill tumor cells through granzyme-dependent retargeting J Invest \u00b7 July 2013 BACKGROUND: Many cancers, including melanoma, exclusively express constitutive proteasomes (cPs) and are unable to express immunoproteasomes (iPs). In contrast, mature DCs used for immunotherapy exclusively express iPs. Since proteasomes generate peptides ... June 2013 B lymphocyte stimulator (BLyS) is a cytokine involved in differentiation and survival of follicular B cells along with humoral response potentiation. Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to e ... [BLyS levels correlate with vaccine-induced antibody Sci U S A \u00b7 January 2, 2013 Bispecific antibodies (bscAbs), particularly those of the bispecific T-cell engager (BiTE) subclass, have been shown to effectively redirect T cells against cancer. Previous efforts to target antigens expressed in both tumors and normal tissues have produc ... [Systemic administration of a Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases. A prominent side effect of TMZ is induction of profound lymphopenia, which some suggest may be ... [Myeloablative temozolomide enhances CD8 T-cell responses to vaccine and is required for efficacy against brain tumors in mice. ](/publication/932529) [Full 2012 Dendritic cells are highly specialized antigen-presenting cells (APC), which may be isolated or generated from human blood mononuclear cells. Although mature blood dendritic cells normally represent 0.2% of human blood mononuclear cells, their frequency c ... [Isolation and generation 1, 2012 [FEASIBILITY OF AMPLIFIED CD133((+)) BRAIN TUMOR STEM CELL RNA-PULSED DENDRITIC CELLS FOR THE TREATMENT OF PATIENTS WITH ](/publication/928855) [Link to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310971300202&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [EX VIVO GENERATION OF CENTRAL MEMORY-LIKE ANTI-TUMOR T CELLS TO TREAT MALIGNANT BRAIN TUMORS ](/publication/928856) [Link to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310971300185&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [Cite](/publication/928856#cite) Journal Article Plos One \u00b7 2012 BACKGROUND: Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity receptor (IL-2R/CD25) can enhance anti-tumor immunotherapy ... [A of IL-2R blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity [CYTOMEGALOVIRUS-SPECIFIC IN PATIENTS WITH GBM ](/publication/861314) [Link to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [Cite](/publication/861314#cite) Journal Article Neuro IN GLIOBLASTOMA ](/publication/861333) [Link to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600158&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [Cite](/publication/861333#cite) Journal Article Blood \u00b7 September 15, 2011 Lymphodepletion augments adoptive cell transfer during antitumor immunotherapy, producing dramatic clinical responses in patients with malignant melanoma. We report that the lymphopenia induced IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans. ](/publication/741865) [Full text](https://dx.doi.org/10.1182/blood-2011-02-334565) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/21768296) [Cite](/publication/741865#cite) Journal Article Journal [Reply 2011 Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation widely expressed in glioblastoma multiforme (GBM) and other neoplasms, but absent from normal tissues. Immunotherapeutic targeting of EGFRvIII eliminate neoplastic c ... lymphopenia enhances tumor-specific immune responses glioblastoma. ](/publication/741860) November 1, 2010 PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed ... [Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. ](/publication/741857) [Link to \u00b7 August 2010 OBJECT: Convection-enhanced delivery (CED) is a novel intracerebral drug delivery technique with considerable promise for delivering therapeutic agents throughout the CNS. Despite this promise, Phase III clinical trials employing CED have failed to meet cl ... [Poor drug distribution as a possible explanation for the results of the PRECISE trial. ](/publication/741859) [Full text](https://dx.doi.org/10.3171/2009.11.JNS091052) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/20020841) [Cite](/publication/741859#cite) Journal Article Brain Pathol \u00b7 October 2009 Given the highly infiltrative growth pattern of malignant glioma and the lack of specificity associated with currently available treatment regimens, alternative strategies designed to eradicate cancer cells while limiting collateral toxicity in normal tiss ... [EGFRvIII-targeted vaccination October 2009 Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by nonspecific toxicity. Immunologic targeting of tumor-specific gene mutations, however, may allow more precise ... [An epidermal growth factor receptor variant III-targeted vaccine is in May 20, 2009 2034 Background: TRegs are increased in patients with GBM and constitutively express the high affinity interleukin-2 receptor (IL-2R). Treatment with an antibody that blocks IL-2R signaling functionally inactivates and eliminates TRegs without inducing a ... [Effect of daclizumab on item](http://www.ncbi.nlm.nih.gov/pubmed/27964629) [Cite](/publication/1163133#cite) \u00b7 May 20, 2009 2021 Background: Unlike conventional therapies for GBM, immunologic targeting of tumor-specific gene mutations allows precise eradication of neoplastic cells with reduced toxicity. EGFRvIII is a constitutively activated and immunogenic mutation not express ... [Epidermal growth factor receptor variant GBM. ](/publication/1163134) [Link to item](http://www.ncbi.nlm.nih.gov/pubmed/27964605) [Cite](/publication/1163134#cite) Journal Clinical \u00b7 May 20, 2009 [Effect of daclizumab on T-Reg counts and GBM [Link to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606602182&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [Cite](/publication/861270#cite) Conference Journal of Clinical Oncology \u00b7 May 20, 2009 [Epidermal growth factor receptor variant III (EGFRvIII) GBM ](/publication/861325) [Link to \u00b7 May 1, 2009 [RNA Transfected Dendritic Cell Vaccines Targeting Human April 1, 2009 [INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS DIAGNOSED [The role of tregs in human glioma patients and their STAT-3 [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/20214040) [Cite](/publication/757992#cite) Journal Article J Immunol Methods \u00b7 November 30, 2008 The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms. As such it tumor-specific target for antitumor immunothera ... [Detection of October 2008 Conventional therapies for malignant gliomas (MGs) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by non-specific toxicity. Immunologic targeting of tumor-specific gene mutations, however, may allow more precise erad ... [Tumor-specific immunotherapy targeting the to item](https://www.ncbi.nlm.nih.gov/pubmed/18539480) [Cite](/publication/722136#cite) Cancer Res \u00b7 September 15, 2008 PURPOSE: Activation of signal transducers and activators of transcription 3 (STAT3) has been identified as a central mediator of melanoma growth and metastasis. We hypothesized that WP1066, a novel STAT3 blockade agent, has marked antitumor activity, even ... [A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. ](/publication/757993) item](https://www.ncbi.nlm.nih.gov/pubmed/18794085) [Cite](/publication/757993#cite) Journal Article Neuro Oncol \u00b7 June 2008 The purpose of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and intracerebral distribution of a recombinant toxin (TP-38) targeting the epidermal growth factor receptor in patients with recurrent malignant brai ... [Intracerebral infusion of an EGFR-targeted toxin in tumors. ](/publication/724105) [Full text](https://dx.doi.org/10.1215/15228517-2008-012) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/18403491) [Cite](/publication/724105#cite) Journal Article Journal Clinical Oncology \u00b7 May 20, 2008 [Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM ](/publication/861322) [Full text](https://dx.doi.org/10.1200/jco.2008.26.15_suppl.2011) [Cite](/publication/861322#cite) Journal Article Journal of Clinical Oncology \u00b7 May 20, 2008 [Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed Article February 2008 Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization. Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia. Alt ... [Immunological responses in a patient with glioblastoma multiforme treated with sequential courses January 2008 PURPOSE: Immunotoxins as anti-cancer therapeutics have several potential advantages over conventional agents including a high specificity, extraordinary potency, and a lack of an identified mechanism for resistance. It has been clearly demonstrated that Ps ... [EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. ](/publication/722143) [Full [Cite](/publication/722143#cite) Journal of Clinical Oncology \u00b7 June 20, 2007 [Temozolomide as a vaccine adjuvant in GBM ](/publication/1366840) [Link to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043700329&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [Cite](/publication/1366840#cite) Journal Article Clin Cancer Res \u00b7 April 1, 2007 PURPOSE: Patients with malignant glioma suffer global compromise of their cellular immunity, characterized by dramatic reductions in CD4(+) T cell numbers and function. We have previously shown that increased regulatory T cell (T(reg)) fractions in these p ... [Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ without T-cell function. text](https://dx.doi.org/10.1158/1078-0432.CCR-06-2070) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/17404100) [Cite](/publication/722138#cite) Clin \u00b7 December 15, 2006 PURPOSE: Analyses of T-cell mRNA expression profiles in glioblastoma multiforme has not been previously reported but may help to define and characterize the immunosuppressed phenotype in patients with this type of cancer. EXPERIMENTAL DESIGN: We did microa ... [Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/17189402) [Cite](/publication/696789#cite) Journal October The topoisomerase is highly tumoricidal against (GBM) in vitro. However, systemic administration of 9NC has not shown the expected efficacy in clinical trials. This failure may be due to the ... Journal Article Biological Psychiatry \u00b7 June 2006 Attrition is a ubiquitous problem in randomized controlled clinical trials (RCT) of psychotropic agents that can cause biased estimates of the treatment effect, reduce statistical power, and restrict the generalizability of results. The extent of the probl ... [Attrition psychopharmacology. ](/publication/669987) [Cite](/publication/669987#cite) Journal Article Cancer Res \u00b7 March 15, 2006 Immunosuppression is frequently associated with malignancy and is particularly severe in patients with malignant glioma. Anergy and counterproductive shifts toward T(H)2 cytokine production are T-cell defects in these patients whose etiolog ... [Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. ](/publication/740656) [Full text](https://dx.doi.org/10.1158/0008-5472.CAN-05-3773) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/16540683) [Cite](/publication/740656#cite) Cancer Res \u00b7 February 15, 2006 PURPOSE: The toxicity and antitumor activity of regional intrathecal delivery of an oncolytic recombinant poliovirus, PVS-RIPO, EXPERIMENTAL to item](https://www.ncbi.nlm.nih.gov/pubmed/16489093) Clinical Research \u00b7 December 15, 2005 [Expression profiling of CD4+ and CD8+ T cells October 1, 2004 [Dendritic cell vaccine for intracranial tumors I (DC Victori trial) ](/publication/861326) [Link to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000224332400142&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [Cite](/publication/861326#cite) Journal Article Clin Cancer Res \u00b7 July 15, 2004 PURPOSE: Spread to the central nervous system (CNS) and the leptomeninges is a frequent complication of systemic cancers that is associated with serious morbidity and high mortality. We have evaluated a novel therapeutic approach against CNS complications ... [Treatment of intracerebral neoplasia Cancer Res \u00b7 May 1, 2004 PURPOSE: We have reported previously that tumors expressing wild-type epidermal growth factor receptor (EGFR) in a murine sensitive to the EGFR tyrosine kinase inhibitor gefitinib, whereas [Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant 15, 2003 PURPOSE: The monoclonal (MAb) trastuzumab (Herceptin) such macromolecule therapeutic agents to intracerebral metastases, however, is limited by the tight junctions ... [Efficacy of intracerebral microinfusion of trastuzumab in breast ](/publication/694196) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/14654531) [Cite](/publication/694196#cite) Journal Article J Neurooncol \u00b7 October 2003 TP-38 is a recombinant chimeric targeted toxin composed of the EGFR binding ligand TGF-alpha and a genetically engineered form of the Pseudomonas exotoxin, PE-38. After in vitro and in vivo animal studies that showed specific activity and defined the maxim ... [Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment text](https://dx.doi.org/10.1023/a:1026290315809) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/14649883) [Cite](/publication/709787#cite) Journal Article Res \u00b7 September 15, 2003 PURPOSE: The epidermal growth factor receptor (EGFR) is often amplified and structurally rearranged in malignant gliomas and other tumors such as breast and lung, with the most common mutation being EGFRvIII. In the study described here, we tested in mouse ... [Epidermal growth factor receptor VIII peptide vaccination is established intracerebral tumors. ](/publication/678252) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/14519652) [Cite](/publication/678252#cite) Journal Article J Neurooncol \u00b7 2003 Despite advancements in therapeutic regimens, the prognosis remains poor for patients with malignant gliomas. Specificity has been an elusive goal for current modalities, but immunotherapy has emerged as a potential means of designing more tumor-specific t ... [The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. [Full text](https://dx.doi.org/10.1007/BF02700031) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/12952297) [Cite](/publication/675210#cite) Journal Article Res \u00b7 November 2002 Featured Publication Iressa (ZD1839) is a p.o.-active, selective, epidermal growth inhibitor (EGFR-TKI) that blocks signal transduction pathways implicated in cancer cell proliferation, survival, and host-dependent processes promoting cancer gro ... [Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with Article Cancer Res \u00b7 June 15, 2002 Featured Publication The gene most commonly altered in human glioblastomas is the epidermalgrowth factor receptor (EGFR). We profiled transcripts induced by mutantEGFR to better understand its role in tumor progression. The pattern found suggested enhanced tumor invasion. The ... [Mutant epidermal growth factor receptor up-regulates ](/publication/669982) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/12067969) [Cite](/publication/669982#cite) Journal Article Neurosurgery \u00b7 January 2002 Featured Publication OBJECTIVE: Dendritic cells (DCs) are specialized cells of the immune system that are capable of generating potent immune responses that are active even within the \"immunologically privileged\" central nervous system. However, immune responses generated by D ... [Dendritic cells pulsed with a tumor-specific peptide 2001 Dendritic cells are highly specialized antigen-presenting cells (APC), which may be isolated or generated from human blood mononuclear cells. Although mature blood dendritic cells normally represent 0.2% of human blood mononuclear cells, their frequency ca ... [Isolation and generation to item](https://www.ncbi.nlm.nih.gov/pubmed/18432844) Biotechniques \u00b7 January 2001 Featured Publication Microarray technology is a powerful tool for generating expression data on a large number of genes simultaneously. However, as for any assay, it must be reproducible to give confidence in the results. Using a classical statistical method--the factorial des ... to item](https://www.ncbi.nlm.nih.gov/pubmed/11196312) [Cite](/publication/669956#cite) Int J Cancer \u00b7 December 15, 2000 Combinatorial variation of CDR3 of V(H) and V(L), followed by phage display, was used to select affinity mutants of the parental anti-epidermal growth factor receptor-vIII (EGFRvIII) scFv increased specific ... [Increased binding Clinical Cancer Research \u00b7 November 1, 2000 [Oral administration of the specific EGFR tyrosine to item](http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000165409000338&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92) [Cite](/publication/861324#cite) Journal Article Cancer Res \u00b7 October 2000 Featured Publication Intracerebral microinfusion (ICM) is an innovative technique of delivering therapeutic agents throughout large portions of the brain that circumvents the blood-brain barrier, minimizes systemic toxicity, and provides a homogeneous distribution of the infus ... [Temozolomide delivered by intracerebral microinfusion is safe and malignant gliomas in [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/11051269) [Cite](/publication/694168#cite) Journal Article Proc Natl Acad Sci U S A \u00b7 June 20, 2000 Featured Publication The epidermal growth factor receptor (EGFR) is often amplified and rearranged structurally in tumors of the brain, breast, lung, and ovary. The most common mutation, EGFRvIII, is characterized by an in-frame deletion of 801 base pairs, resulting in the gen ... [Unarmed, tumor-specific antibody to item](https://www.ncbi.nlm.nih.gov/pubmed/10852962) [Cite](/publication/678308#cite) Journal Article J Neuroimmunol \u00b7 February 1, 2000 Featured Publication To evaluate the efficacy and toxicity of dendritic cell (DC) based therapy for intracerebral gliomas, we utilized a cell line derived from an astrocytoma that arose spontaneously in a VM/Dk mouse. antibody labeled with is of interest as an endoradiotherapeutic agent for the treatment of brain tumors. To facilitate the investigation of 211At-label [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/10487576) [Cite](/publication/694107#cite) Journal Article Clin Res \u00b7 September 1999 The incidence of neoplastic meningitis is on the rise. Neoplastic meningitis can result from a direct seeding of the neuraxis by primary brain tumors or by hematogeneous spread of systemic solid tumors. A frequent genetic alteration in primary brain tumors ... [Regional treatment of epidermal growth Res \u00b7 June 1999 A single-chain antibody fragment, MR1(scFv), with specific binding to epidermal growth factor receptor-vIII (EGFRvIII), was produced, radiolabeled, and evaluated for biodistribution in human glioma-bearing athymic mice. The mutant receptor EGFRvIII [125I-labeled anti-epidermal growth factor to item](https://www.ncbi.nlm.nih.gov/pubmed/10389943) May 1999 Neoplastic meningitis (NM) results from leptomeningeal dissemination of cancers arising within the central nervous system or metastasizing to the leptomeninges from systemic neoplasms. The inability to produce therapeutic drug levels intrathecally drug azathioprine (AZA), a multitissue rodent carcinogen and IARC-classified human carcinogen, was investigated using transgenic lacZ mice (MutaMouse). Male animals (n = 5 per group) were dosed w ... [Analysis of gene mutations and in item](https://www.ncbi.nlm.nih.gov/pubmed/10529737) [Cite](/publication/669953#cite) Journal Article J Neurooncol \u00b7 1999 The current study was designed to evaluate the toxicity and activity of Spartaject Busulfan, a microcrystalline preparation of busulfan, following its intrathecal administration into a nude rat model of human neoplastic meningitis. Animals were treated thr item](https://www.ncbi.nlm.nih.gov/pubmed/10720203) [Cite](/publication/694198#cite) Journal Article Clinical Cancer Research \u00b7 1999 A single-chain antibody fragment, MR1(scFv), with specific binding to epidermal growth factor receptor-vIII (EGFRvIII), was produced, radiolabeled, and evaluated for biodistribution in human glioma-bearing athymic mice. The mutant receptor EGFRvIII [125I-labeled anti-epidermal growth factor ](/publication/757994) [Cite](/publication/757994#cite) Journal Article J Neuroimmunol \u00b7 June 1, 1998 We have previously reported that local secretion of either TNF-alpha or TGF beta1 by intracerebral SMA-560 malignant glioma tumor cells can reduce or eliminate tumor growth in mice. However, the use of TNF-alpha, while improving the overall survival of tum ... [Local production of TGF beta1 inhibits cerebral edema, enhances induced apoptosis J Neurovirol \u00b7 April 1998 Any immunotherapeutic approach to cancer cell eradication is based upon the specific recognition of neoplastic cells and the sparing of surrounding normal tissue; perhaps nowhere is this distinction more important than within the central nervous system, du ... [The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as target. [Link December 1997 OBJECTIVE: The promise of immunotherapies developed against brain tumors in animal models has not been realized in human clinical trials. This may be because of the routine use of rodent tumors artificially induced by chemicals or viruses that do not accur ... [Characterization of a spontaneous murine September 1997 An active immunotherapeutic strategy using transfected allogeneic cells for targeting the mutant epidermal growth factor receptor (EGFRvIII) on intracranial tumors was examined. cytotoxic cytotoxic responses against Neurovirol \u00b7 May 1997 [Viruses and oncogenes in brain tumors. ](/publication/675302) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/9179801) [Cite](/publication/675302#cite) Journal Article Cancer Res \u00b7 April 15, 1997 Monoclonal antibody (mAb) L8A4, specific for the tumor-associated mutant epidermal growth factor receptor variant III (EGFRvII), is internalized and degraded after cell binding. Four paired-label experiments were performed in athymic mice bearing EGFRvIII- ... [Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl Journal Article Cancer Chemother Pharmacol \u00b7 1997 The prognosis for patients with malignant gliomas continues to be dismal. The high degree of resistance of gliomas to nitrosourea-based chemotherapy is one major factor in poor treatment outcome. The identification of O6-alkylguanine-DNA alkyltransferase ( ... [Intraarterial Journal Journal of Radiation Oncology*Biology*Physics \u00b7 January 1997 [2013 The impact of hypoxia and oxygenation modification on the radiation response of an Acad Sci U S A \u00b7 September 17, 1996 Vaccination with cytokine-producing tumor cells generates potent immune responses against tumors outside the central nervous system (CNS). The CNS, however, is a barrier to allograft and xenograft rejection, and established tumors within the CNS have faile ... [Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates cell-mediated immunity against tumors located system. Journal Article Nucl Biol \u00b7 May 1996 When labeled using the Iodogen method, a chimeric antibody composed of the human IgG2 constant region and the variable regions of murine anti-tenascin 81C6 exhibited superior uptake in human glioma xenografts compared with its murine parent. In the current ... [Chimeric anti-tenascin antibody 81C6: increased tumor ](/publication/674968) [Full text](https://dx.doi.org/10.1016/0969-8051(96)00021-2) Biol Phys \u00b7 April 1, 1996 PURPOSE: The present study undertook to establish the dose (LD) of systematically administered (via tail vein) sodium [211At]astatide that would kill 10% (LD10) of exposed animals in two mouse models and to evaluate the resulting histologic lesions. METHOD ... [Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c text](https://dx.doi.org/10.1016/s0360-3016(96)85013-9) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8641929) [Cite](/publication/694187#cite) Journal Article Recent Results Cancer Res \u00b7 1996 [Two approaches for enhancing radioimmunotherapy: \u00b7 December 1995 LMB-1 (B3-LysPE38) is an immunotoxin composed of the tumor-reactive monoclonal antibody B3 and a engineered form of exotoxin. Monoclonal antibody B3 reacts with a carbohydrate epitope that is found on a number of solid tumors (e.g., ... [Efficacy of compartmental administration of immunotoxin [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/9815955) [Cite](/publication/709904#cite) Journal Article Cancer Res \u00b7 October 1, 1995 Amplification and rearrangement of the epidermal growth factor receptor (EGFR) gene are characteristics of many types of tumors. One class of EGFR mutations, EGFRvIII, is characterized by an in-frame deletion resulting in a truncated external domain of the ... [Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. ](/publication/675061) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/7671250) [Cite](/publication/675061#cite) Journal Article Cancer Res \u00b7 September 1, 1995 Malignant gliomas will affect 15,000-17,000 Americans each year and carry a dismal prognosis. Adjuvant chemotherapy is hampered by inadequate drug delivery, systemic toxicity, and a markedly variable biological sensitivity. Intraarterial (i.a.) therapy may ... [Intraarterial administration of Proc Natl Acad U S A \u00b7 March 28, 1995 LMB-7 [B3(Fv)-PE38] is a single-chain immunotoxin constructed from the from PE38. Antibody B3 recognizes a carbohydrate epitope found on solid tumors that frequently invade the intrathec ... [Intrathecal administration item](https://www.ncbi.nlm.nih.gov/pubmed/7708720) [Cite](/publication/709681#cite) Journal Article J Med \u00b7 September 1994 UNLABELLED: Four dogs with histologically confirmed osteogenic sarcoma were studied with PET following intravenous injection of the 18F-labeled Fab fragment of TP-3, a monoclonal antibody specific for human and canine osteosarcomas. METHODS: The antibody f ... [PET imaging of osteosarcoma in dogs using a antibody Fab fragment. ](/publication/669959) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8071702) [Cite](/publication/669959#cite) Journal Article Cancer Res \u00b7 September 1, 1994 We report the activity and toxicity of intrathecal melphalan in the treatment of human neoplastic meningitis in the subarachnoid space of athymic nude rats. Animals received injections via chronic indwelling subarachnoid catheters with 5 x 10(5) or 5 x 10( ... [Intrathecal melphalan therapy ](/publication/694097) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8062269) [Cite](/publication/694097#cite) Journal Article Cancer Res \u00b7 September 1, 1994 Because of their short range and high linear energy transfer, alpha-particles may be particularly effective in the treatment of neoplastic meningitis. Monoclonal antibody item](https://www.ncbi.nlm.nih.gov/pubmed/8062270) [Cite](/publication/694183#cite) The murine anti-tenascin monoclonal antibody 81C6, following iodination, has been shown to be an efficient localizing and therapeutic agent in both subcutaneous and intracranial human glioma xenograft models in athymic mice and rats. Similarly, effective m ... [Generation and characterization of a mouse/human chimeric J Neuroimmunol \u00b7 July 1993 We have previously demonstrated antibody production to a glioma-associated variant form of the human epidermal growth factor receptor in rabbits that had received a synthetic peptide mimicking the unique primary structure of the variant protein as immunoge ... [Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor ](/publication/674983) [Full text](https://dx.doi.org/10.1016/0165-5728(93)90246-u) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/8360327) [Cite](/publication/674983#cite) Journal Article Cancer Res \u00b7 May 15, 1993 The addition of chemotherapy, notably using nitrosoureas, in the treatment of patients with glioblastoma multiforme has resulted in only modest improvements in long-term patient survival over the use of surgical intervention and irradiation alone. Intraart ... [Intraarterial therapy of Conference of Neuropathology and Experimental Neurology \u00b7 May 1993 [NEUROPATHOLOGY OF MULTIPLE VERSUS SINGLE DOSE INTRATHECAL MELPHALAN IN RATS ](/publication/861329) [Full text](https://dx.doi.org/10.1097/00005072-199305000-00152) [Cite](/publication/861329#cite) Journal Article Cancer Research \u00b7 January 1, 1993 The addition of chemotherapy, notably using nitrosoureas, in the treatment of patients with glioblastoma multiforme has resulted in only modest improvements in long-term patient survival over the use of surgical intervention and irradiation alone. Intraart ... [Intraarterial Therapy of Biochem Biophys Commun 15, 1991 Malignant human glioma D-298 MG amplifies a rearranged epidermal growth factor receptor (EGFR) gene (c-erbB proto-oncogene), resulting in an in-frame deletion of 83 amino acids in domain IV of the extracellular domain of the EGFR. EGF and transforming grow ... [Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. ](/publication/674957) Acad Sci U S A \u00b7 June 1990 We have investigated human gliomas that amplify and rearrange the epidermal growth factor receptor gene, with generation of an in-frame deletion mutation of 802 nucleotides in the external domain. This in-frame deletion mutation generates a local amino aci ... [Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/1693434) [Cite](/publication/675312#cite) Journal Article Cancer Res \u00b7 March 15, 1990 The administration of radiolabeled monoclonal antibodies to improve the treatment of malignant gliomas is dependent upon achieving effective tumor radiation dose while sparing normal tissues. We have evaluated the efficacy of 131I-labeled F(ab')2 fragment to item](https://www.ncbi.nlm.nih.gov/pubmed/2407345) [Cite](/publication/675090#cite) Journal Article Cancer Res \u00b7 March 15, 1990 Neoplastic meningitis can result from leptomeningeal dissemination of a variety of cancers. We now report the development of animal models of human neoplastic meningitis and activity of intrathecal ... [Activity of neoplastic ](/publication/693693) [Link to item](https://www.ncbi.nlm.nih.gov/pubmed/2306744) [Cite](/publication/693693#cite) Conference and Experimental Neurology \u00b7 May 1989 [A NUDE RAT MODEL OF LEPTOMENINGEAL TUMOR DISSEMINATION (LTD) OF HUMAN MEDULLOBLASTOMA ](/publication/861321) [Full text](https://dx.doi.org/10.1097/00005072-198905000-00173) [Cite](/publication/861321#cite) Journal Article N-succinimidyl-3-(tri-n-butylstannyl)benzoate ... [Synthesis J Obstet Gynecol \u00b7 July 1987 A woman with a history of \"in utero\" diethylstilbestrol exposure but no prior uterine surgery presented with an acute abdomen at 21 weeks' gestation. She had hemoperitoneum associated with placenta percreta. ... [Acute abdomen [Full item](https://www.ncbi.nlm.nih.gov/pubmed/3605246) [Cite](/publication/669985#cite) Journal Article J Child Neurol \u00b7 July 1986 Antineural antibodies have been described in sera of patients with neurodegenerative disorders. We looked for the presence of those antibodies in the sera of patients with spinocerebellar degeneration. Serum IgG from four patients with familial [Immunocytochemical [Cite](/publication/669957#cite) Article J \u00b7 1986 Two continuous human glioma-derived cell lines, UC-11MG and UC-302MG were established in our laboratory. Both cell lines persistently showed cytologic features similar to those of their respective original tumors. UC-11MG expressed glial fibrillary Journal Neuropathology and Experimental Neurology \u00b7 January 1, 1982 [RG2, a clone of nitrosourea-induced rat glioma, can be used studying astrocytic differentiation in vitro ](/publication/757996) [Full text](https://dx.doi.org/10.1097/00005072-198205000-00091) [Cite](/publication/757996#cite) Journal Article Proceedings of the Royal Society of Medicine, Not Available \u00b7 March "}